Please provide your email address to receive an email when new articles are posted on . The PCA3 urine test accurately predicted whether a prostate biopsy would detect cancer in a prospective ...

Gen-Probe Incorporated and DiagnoCure Inc. has announced that the companies have signed an amendment to their 2003 license agreement, establishing new FDA submission milestones and key distribution ...

QUEBEC CITY, May 25, 2012 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a Quebec life sciences company that develops and commercializes high-value cancer diagnostic tests, reported that the PROGENSA PCA3 ...

Prostate cancer metastasis, the noncanonical Wnt pathway, and the transcription factor PITX2. Background: Several studies using APTIMA PSA assay have demonstrated that PCA3 score is superior to serum ...

A simple urine test leads to more accurate diagnoses, fewer false-positive results for prostate cancer. The experimental biomarker test more accurately detects prostate cancer than any other screening ...

The role of the prostate cancer antigen 3 (PCA3) assay (Hologic/Gen-Probe) in ruling out prostate cancer in men presenting for a repeat biopsy has been supported by a large American study. However, ...

Last week brought more positive news for DiagnoCure Inc. (T.CUR) and the Progensa PCA3 prostate cancer test including the final recommendation by the U.S. Preventative Services Task Force (:USPSTF) ...

Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223. Germ-line single nucleotide ...

Prostate cancer is one of the largest killers among males worldwide. Until recently, prostate cancer diagnosis has relied on a combination of prostate-specific antigen (PSA) level, digital rectal ...

Test aims to help clinicians decide whether patients who test negative will need further biopsy procedures. FDA approved Gen-Probe’s Progensa® PCA3 (Prostate Cancer gene 3) assay, which the firm ...

DiagnoCure reported positive data at the American Urological Association (AUA) meeting from a multicenter study to independently validate the Progensa PCA3 assay for the detection of prostate cancer ...